European Pharmaceutical Review

JANUARY 23, 2025

1 all revenue in big pharma now come from dealmaking, confirming a need for robust inorganic growth and value creation strategies The year began with this forecast holding true, as the pharmaceutical industry declared major M&A deals including Johnson & Johnsons acquisition of Intra-Cellular Therapies, Inc. trillion Firepower.

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

PM360

JANUARY 24, 2025

For the past nine years, EVERSANA INTOUCH has done a look ahead: a forecast based on input from leaders on what trends may shape pharma marketing in the year ahead. Lets take a closer look at each of these trends: Applied AI: As excitement continues to grow and AI becomes more real, how is it being deployed by pharma marketers?

Marketing 52

Marketing Pharma Healthcare Healthcare 52

Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.

Patients 111

Patients Safety Sales Manufacturing 111

pharmaphorum

DECEMBER 1, 2022

Billion by 2028. Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Exploring the implementation of complex in-vitro models for drug development. Who Should Attend?

Engineering 52

Engineering Management Pharmaceutical Media 52

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. The Cost-Saving Alternative: What are Biosimilars?

Marketing 52

Marketing Healthcare Healthcare Physicians 52

PM360

SEPTEMBER 21, 2023

Under the pathway, manufacturers can use safety and efficacy data from existing products in their applications for their own products. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

FEBRUARY 13, 2023

According to the GlobalData Pharma Intelligence Center, there are currently 71 PROTACs in development in the oncology pipeline by non-academic developers, mostly clustering in the preclinical and discovery phases, with only 14 agents in clinical stages. Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas.

Competition 59

Competition Safety Patients Pharmaceutical 59